On January 23, 2024 Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, reported that Gerard Michel, CEO, will participate in a fireside chat moderated by Bill Maughan Ph.D., Senior Analyst at Canaccord Genuity, at the Lytham Partners 2024 Investor Select Conference. Management will also host virtual one-on-one meetings with investors (Press release, Delcath Systems, JAN 23, 2024, View Source [SID1234639427]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Company Webcast

The webcasted fireside chat will take place at 8:45 AM ET on Thursday, February 1, 2024. The webcast can be accessed at View Source or on the Company’s website at delcath.com. The webcast will also be available for replay following the event.

1×1 Meetings

Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1×[email protected] or register for the event at View Source

Further information on the conference is available at View Source

On January 23, 2024 BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, reported a master agreement with Duke University School of Medicine, one of the nation’s leading institutions for healthcare education, clinical healthcare provision, biomedical research, and community engagement, to collaborate on multiple research projects across lung cancer, gastrointestinal, genitourinary and skin cancers (Press release, BostonGene, JAN 23, 2024, View Source [SID1234639443]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The strategic partnership allows Duke physicians and researchers to leverage BostonGene’s expertise to drive the molecular and cellular characterization of the patient’s tumor, microenvironment and immune system and test its predictive value in response to treatment. For cancer patients undergoing treatment at Duke University, including those participating in clinical trials, BostonGene will provide state-of-the-art analytics, interpretation and visualization of big data obtained from analysis of patients’ genomic, transcriptomic, cell phenotyping, proteomic and imaging studies.

"Our collaboration with BostonGene is a testament to our commitment to excellence in healthcare and research. This study will enable us to explore the boundaries of predictive biomarkers and potentially offer new treatment options to patients," said Jeffrey Clarke, MD, Associate Professor of Medicine at Duke University School of Medicine.

"The partnership with Duke University signifies a pivotal step in actualizing AI-driven molecular insights to transform patient care," said Nathan Fowler, MD, Chief Medical Officer at BostonGene. "Our combined expertise will study the complex genetic landscape of a patient’s tumor, microenvironment and immune system, paving the path towards personalized treatments for all patients."

In its flagship study, led by Dr. Clarke at Duke and BostonGene molecular profiling and comprehensive analyses will be conducted on a meticulously annotated real-world cohort of non-small cell lung cancer (NSCLC) patients who received treatment with either checkpoint inhibitors alone or in conjunction with chemotherapy. The study’s primary objective is to assess predictive biomarkers that can more accurately pinpoint the subset of patients poised to derive maximum benefits from immunotherapy in the context of metastatic NSCLC.

On January 23, 2024 Genmab A/S (Nasdaq: GMAB) reported that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO in the U.S.), as reported by Johnson & Johnson were USD 9,744 million in 2023 (Press release, Genmab, JAN 23, 2024, View Source [SID1234639428]). Net trade sales were USD 5,277 million in the U.S. and USD 4,467 million in the rest of the world. Genmab receives royalties on the worldwide net sales of DARZALEX, both the intravenous and SC products, under the exclusive worldwide license to Janssen to develop, manufacture and commercialize daratumumab.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On January 23, 2024 bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer and lung disease, reported that India’s Office of the Controller General of Patents, Designs and Trade Marks has issued a Certificate of Grant of Patent to bioAffinity subsidiary OncoSelect Therapeutics, LLC for its compositions and methods to treat cancer using chemotherapeutic agents conjugated to porphyrins, resulting in targeted delivery of the drugs (Press release, BioAffinity Technologies, JAN 23, 2024, View Source [SID1234639444]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Indian patent, titled "Porphyrin Compounds and Compositions Useful for Treating Cancer" is an important addition to bioAffinity Technologies’ patent portfolio, which includes 16 awarded U.S. and foreign patents and 23 pending patent applications related to its porphyrin-based diagnostic platform and cancer treatment therapeutics.

"India’s patent is an acknowledgement of the value of our ongoing research, development and commercialization of porphyrin-based diagnostics and targeted treatments for lung cancer and other diseases," bioAffinity Technologies’ President and CEO Maria Zannes said. "We are committed to improving the outcome for cancer patients around the world, beginning with lung cancer, the deadliest cancer killer. Strong intellectual property protection for our innovative science benefits not only patients in need of treatment and their physicians, but also our research team and our shareholders as well."

bioAffinity Technologies’ first product, CyPath Lung, is a porphyrin-based diagnostic test for early-stage lung cancer. Physicians use CyPath Lung for patients at high risk for developing lung cancer, often after recommended screening reveals indeterminate pulmonary lung nodules that may or may not be malignant. CyPath Lung is a noninvasive test that uses advanced flow cytometry and artificial intelligence to differentiate patients with cancer from those who do not have the disease.

On January 23, 2024 HEPHAISTOS-Pharma, a biotechnology company developing next generation immunotherapies against cancer, reported that it has raised a €2 million seed round to finance GMP transfer and advance its lead candidate towards the clinic (Press release, HEPHAISTOS-Pharma, JAN 23, 2024, View Source [SID1234639429]). The round was co-led by xista science ventures and the Foundation Fournier-Majoie, with the participation of Noshaq.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

« The Foundation is very pleased to be part of HEPHAISTOS-Pharma thanks to this financing round. The valuable and dedicated team developed a promising TLR4 compound that will be used systemically which will bring to the oncologists a best-in-class product for their cancer patients. We are eager to help the company bring to the clinic this innovative program. » said Jerome Majoie, CEO and Chairman at Fournier- Majoie Foundation.

"We are very proud to be joined by institutional investors" said Frederic CAROFF, CEO, and co-founder of HEPHAISTOS-Pharma. "They bring the necessary funds to match our non-dilutive financing, but also the expertise and network that will help structure the company. They will play a critical role in the success of HEPHAISTOS as we move our platform to the clinic. We are also thankful to our historical investors and new business angels from Angels Santé, who joined the round."

The proceeds from this financing round will enable HEPHAISTOS to industrialize its manufacturing process and prepare for the clinical phases, with the goal of advancing its lead candidate, ONCO-Boost, into clinical development for the treatment of solid tumors with high unmet medical needs, in particular sarcoma. Ingrid Kelly, Partner at xista science ventures, commented that « HEPHAISTOS has an impressive set of preclinical data, showing the high potential of their TLR4 agonist ONCO-Boost to tackle solid tumors, particularly in combination with immunotherapies such as checkpoint inhibitors.

The proceeds will also be used to open a new subsidiary in Liège, Wallonia. The objective will be to leverage local state-of -the-art facilities and expertise to explore additional applications and strengthen HEPHAISTOS’ pipeline. "We are delighted to attract HEPHAISTOS to develop part of its activities in our vibrant local ecosystem. In the midst of a challenging market landscape, Noshaq remains a magnet for innovative companies with a disruptive approach and high-level management" said Eric Brandt, Investment Manager at NOSHAQ.